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Abstract 
 Kidney transplantation is considered the best therapeutic option for 
end stage renal disease (ESRD). Cyclosporine is a potent 
immunosuppressive drug used to prevent graft rejection. Gingival 
hyperplasia is one of the collateral effect of cyclosporine, the exact 
pathogenesis of cyclosporine induced gingival hyperplasia is uncertain, and 
it may interfere with normal oral functions causing unpleasant appearance, 
carry psychological impacts and leads to difficulty in maintaining good oral 
hygiene.  A 28 year old male patient reported to the department of Oral 
Medicine of the School of dentistry, University of Sulaimani, he had renal 
transplantation and he is on long term immunosppressive drug 
(cyclosporine), the patient complains of gingival swelling, intraoral 
examination revealed severe generalized gingival hyperplasia, periodic oral 
examination of kidney transplant patients who are on long term cyclosporine 
drug treatment is important to monitor any signs of gingival hyperplasia, 
reassurance and management based on general medical condition of the 
patient. 
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Introduction  
Kidney transplant (KT) is the most efficient renal replacement 
therapy for a significant number of patients with ESRD (1). Survival of KT 
patients has increased because of improvements in candidates selection and 
study process, surgical techniques, immunosuppressive drugs and protocols, 
and a better surveillance and management of extra-renal risk factors. 
Cyclosporin-A (CsA) is a drug used to prevent rejection of the kidney graft. 
It is a cyclic polypeptide calcineurin inhibitor. Its administration prevents the 
expression of genes for several cytokines whose activity is critical for 
lymphocyte T activation, including interleukins 2 and 4, gamma interferon, 
tumor necrosis factor α and others, thus preventing lymphocyte proliferation. 
The drug is used either alone or combined with other immunosuppressor 
drugs (2). Its use causes collateral effects, such as nephrotoxicity, hirsutism, 
arterial hypertension, dermatosis (2,3) and lymphoproliferative diseases (3).  
Gingival hyperlasia is a collateral effect of Cyclosporine A use. The 
variability of clinical expression of Cyclosporine A -related gingival 
hyperplasia implies a multifactorial pathogenesis. Cyclosporine A blood 
concentration, plaque/gingivitis level, bacterial lipopolysaccharides, and 
alteration of calcium ion cellular influx have been suggested as possible 
factors (4). Gingival hyperplasia may interfere with normal oral functions, 
leave patients with an unpleasant appearance, carry psychological impacts, 
influence compliance with medical therapy, and make it difficult to maintain 
optimal oral hygiene (5). The latter, in turn, may exacerbate GO via bacterial 
overgrowth (4). The immunosuppressive actions of Cyclosporine A may 
allow tissue invasion by micro-organisms, which causes a secondary 
inflammatory response (6).  
We presented a case of cyclosporine induced gingival hyperplasia 
along with the review of the relevant literature  
 
Case report 
A 28 year old male patient attending the department of Oral Medicine 
of the School of dentistry, university of Sulaimani, he had renal 
transplantation and he is on long term immunosppressive drug (cyclosporine) 
for prevention of rejection. This work was approved by the Committee of 
Ethics in Research of the University of Sulaimani. According to Declaration 
of Helsinki, signed consent form was obtained from the patient before 
conducting it. The patient was complained of gingival swelling, intraoral 
examination revealed severe generalized gingival hyperplasia (Figure 1). The 
patient was assured about the cause of his problem as it is related to long 
term cyclosporine immunosuppressive treatment and treated by 
gingivectomy. 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
415 
Figure 1: Cyclosporine-induced gingival hyperplasia in 28 year-old  male renal transplanted 
patient 
 
Disscusion  
Cyclosorin A (CsA) is a powerful immunosuprssant widely used for 
prevention of transplant rejection as well as for management of a number of 
autoimmune conditions such as rheumatoid arthritis (7) CyA is usually 
administered orally. The oral therapeutic dose for immunosuppression is 10 
to 20 mg/kg body weight/day, which results in a serum concentration of 100 
to 400 ng/ml (8). 
The major adverse reactions to cyclosporine therapy are 
nephrotoxicity, hepatoxicity, tremors, hirsutism, hypertension, mild anemia, 
gingival overgrowth and, in rare instances, lymphoma (9). The drug-induced 
gingival enlargement is a side effect of some immunosuppressive drugs such 
as cyclosporine A, which is the drug of choice in kidney transplant patients 
(10). cyclosporin induced gingival overgrowth is more common in pediatric 
organ transplant patients (52%) as compared to adults (11), male were at 
greater risk from developing gingival overgrowth than females (11).   
The precise mechanism of cyclosporine induced gingival overgrowth 
is uncertain. Various investigations for pathogenesis of gingival overgrowth 
support the hypothesis that it is multifactorial(12). Overgrowth in 
cyclosporine treated patients is dependent upon the interaction of several 
factors. These include plaque control, the level of gingival inflammation and 
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extent of periodontal destruction; the dosage and duration of cyclosporine 
therapy; plasma and tissue concentrations of the drug and metabolites; age of 
the patient and perhaps the underlying medical condition (13).  
Cyclosporine-induced gingival overgrowth commences as a papillary 
enlargement which is more pronounced on the labial aspects of the gingiva 
than the palatal or lingual surfaces (14). The papillary enlargement increases 
and adjacent papillae appear to coalesce. This gives the gingival tissues a 
lobulated appearance. Overgrowth is restricted to the width of attached 
gingiva, but can extend coronally and interfere with the occlusion, 
mastication and speech. Cyclosporine induced gingival overgrowth has not 
been reported in edentulous subjects (15). Histologically, it is not known for 
sure if CyA-induced gingival hyperplasia is a true hyperplasia because 
enlargement may not result simply from an increase in the number of cells 
but from the increase in extracellular tissue volume. The overlying 
epithelium is of variable thickness, irregular, and multilayered, with 
acanthosis, parakeratosis and pseudoepitheliomatous proliferation. The epi-
thelial ridges penetrate deep into the subepithelial connective tissue. 
Microscopic examination shows sparsely vascular fibrous connective tissue 
with thick, dense, interlacing bundles of collagen fibers with an 
inflammatory infiltrate, primarily plasma cells. (16) One of the foundations 
of all drug induced gingival overgrowth is drug substitiution, reduction in the 
dose of cyclosporine has been shown to be beneficial, (17), however the 
nature of organ transplant often means that alternative therapy or dose 
reduction is not available. Some patients can use more conventional 
immunosuppressant such as steroid and azathioprine but survival rate are not 
as good new immunosuppressant such as tacrolimus (FK 506) (Prograft), 
rapamycin and mycophenolate mofetil (MMF) Cell Cept may offer some 
hope, as to date these have not been reported in association with gingival 
overgrowth. It should be remembered that the condition for which patient are 
taking these drug can be very difficult to control and physicians may be very 
reluctant to modify an effective drug regime "just for gums" Thus, while it is 
worth asking if drug substitution is possible, the dentist should understand 
that a negative response is not necessarily a disregard for the gingival 
problem, but rather a concern for the debilitating effects of the underlying 
condition. Although the role of plaque has not been clearly defined in most 
medication induced gingival overgrowth, there is no doubt that the resulting 
gingival inflammation can contribute an additional level of enlargement due 
to oedema, regardless of any initiating or contributing effect it may have on 
gingival growth. Control of this inflammatory component of gingival over 
growth, while important in itself, aso aid in determinig if surgical reduction 
is necessary and, additionally, allows for a less hemorrahagic field in any 
subsequent surgical intervention (18)  
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A program of intense oral hygiene failed to prevent the onset of Cs-
induced gingival overgrowth and it was not particularly effective at reducing 
overgrowth (15), but it was of some benefit for general periodontal health, as 
expected . Furthermore chlohexdine (0.12 percent) mouth rinse has been 
reported to reverse recurrent Cs overgrowth following gingivectomy (19)  
Surgery is normally performed for cosmetic/ aesthetic needs before 
any functional need is manifested. In cases where drug therapy is likely to 
continue for many years, psychsocial consideration need to be considered in 
an effort to reduce the frequency and the extend of any surgical intervention. 
While classical external bevel gingivectomy is still a viable treatment option, 
the large denuded connective tissue wound that result can be painful and 
requires careful postoperative care to prevent infection. There is a tendency 
towards the use of either  a total or partial internal bevel gingivectomy 
approach. This technically more demanding approach have the benefit of 
allowing 'primary closure' thus reducing the chance of post operative 
complications, however it requires more time and skill to a accomplish. 
Surgical treatment of PHT-, Cs and CCB-induced gingival overgrowth has 
centered on gingivectomy by conventional methods and, more recently by 
the use of CO2 lasers (20). The CO2 laser has been advocated because of the 
decreased surgical time, rapid postoperative hemostasis and the fact that 
often the underlying medical conditions are relative contraindications for 
conventional surgery. 
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